Alzheimer's Disease Research Center
阿尔茨海默病研究中心
基本信息
- 批准号:10413092
- 负责人:
- 金额:$ 311.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-15 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdvisory CommitteesAlzheimer&aposs DiseaseAwarenessBiologicalBiological MarkersCell physiologyCholesterol HomeostasisClinicalClinical InvestigatorClinical TrialsCollaborationsCommittee MembersCommunitiesDataDisciplineDiseaseEarly DiagnosisEnrollmentEnvironmentFosteringGenesGeneticGenomicsGoalsImmune responseInfrastructureInstitutionInterventionLearning ModuleMissionNerve DegenerationObservational StudyParticipantPathogenesisPathogenicityPathologyPathway interactionsPatient CarePatient RecruitmentsPatientsPharmaceutical PreparationsPreventionResearchResearch InfrastructureResearch PersonnelResourcesTherapeutic TrialsTimeTrainingUnited States National Institutes of HealthUniversitiesVisionWorkamyloid pathologybasecareercommunity organizationsdata managementeducation researchinterdisciplinary collaborationinterestneuroimagingneuroimmunologyneuropathologyoutreachpatient outreachphenomenological modelspreventprogramsranpirnaserecruitsuccesstau Proteinstooltraffickingtranslational scientist
项目摘要
OVERALL PROJECT SUMMARY/ABSTRACT
This is a new application for a P30 ADRC at Columbia University, continuing the tradition of our previous
P50 ADRC that has existed at Columbia since 1989. Building off our prior accomplishments, the overall objective
of the new ADRC is to support and promote cutting-edge research on Alzheimer’s disease (AD) and related
disorders, both locally in our extensive campus and more globally with other institutions and national consortia.
Subsumed within this objective the Center will have a more focused theme. The theme, focusing on ‘biological
pathways’ implicated in AD pathogenesis, was decided on after internal deliberations, discussions with our
External Advisory Committee members, and with NIH project officers. As reviewed throughout the proposal, we
believe that this broad theme has many advantages. It will strengthen the overall objective by better serving our
local community of basic, translational, and clinical investigators; and will generate new tools and resources that
we will share with other institutions, consortia, and organizations. Additionally, the theme will allow each core to
have both general aims that harmonize with other ADRCs and consortia, and theme-guided aims that emerge
from our local strengths. As reviewed below, the theme will allow cores to synergize and work together in
creating a research infrastructure that relate to the clinical phenomenology, neuropathology, neuroimaging, and
genomics of AD.
Since its inception 30 years ago, the ADRC at Columbia has established an elaborate infrastructure for
research, fostered interdisciplinary collaborations, established a rich training environment, and promoted
outreach and patient recruitment. At the same time the Center has become an active participant in a more global
network comprised of other institutions, national consortia, and community organizations. During the many
cycles of the P50 ADRC, the Center has attained most of its goals, as evidenced, for example, by the breadth of
its scientific findings and by its high ranking of enrolled and active patients.
In this proposal for a new P30 ADRC we will build off of these prior accomplishments moving forward, and
will be motivated by two general goals. The first goal is to continue, as in previous cycles, to foster all research
on AD and related disorders, while the second goal is to support the theme. We propose to achieve these goals
through our well-integrated cores, which collectively establishes an infrastructure that generates a rich array of
resources, biospecimens, and expertise. Besides the Administrative Core, these cores include a Clinical Core
led by Dr. Lawrence Honig, a ‘Data Management and Statistical’ Core led by Dr. Howard Andrews, a
Neuropathology Core led by Dr. Andrew Teich, a Biomarker Core led by Dr. Adam Brickman, a Genetics Core
led by Dr. Christiane Reitz, a Neuroimmunology Core led by Dr. Phillip De Jager, an ‘Outreach, Retention, and
Engagement’ Core led by Dr. William (Ted) Huey, and a ‘Research Education’ Module led by Dr. James Noble.
总体项目总结/摘要
这是哥伦比亚大学P30 ADRC的新申请,延续了我们之前的传统
P50 ADRC自1989年以来一直存在于哥伦比亚。在我们先前成就的基础上,
新ADRC的目的是支持和促进阿尔茨海默病(AD)及相关疾病的前沿研究。
疾病,无论是在我们广泛的校园本地和更全球与其他机构和国家财团。
在这一目标下,中心将有一个重点更加突出的主题。主题是“生物
通路的参与AD发病机制,是在内部审议后决定的,与我们的
外部咨询委员会成员和NIH项目官员。在整个提案中,我们
我认为,这一广泛的主题有许多好处。它将通过更好地服务于我们的
基础、翻译和临床研究者的当地社区;并将产生新的工具和资源,
我们会与其他机构,财团和组织分享。此外,该主题将允许每个核心
既有与其他ADRC和联盟协调的总体目标,也有出现的主题导向目标
从我们当地的优势。如下文所述,这一主题将使各核心能够协同增效,共同努力,
创建与临床现象学,神经病理学,神经影像学,
AD基因组学
自30年前成立以来,哥伦比亚的ADRC已经建立了一个精心设计的基础设施,
研究,促进跨学科合作,建立丰富的培训环境,并促进
外展和患者招募。与此同时,该中心已成为一个更加全球化的积极参与者。
该网络由其他机构、国家财团和社区组织组成。在许多
P50 ADRC的周期,该中心已经实现了其大部分目标,例如,
其科学发现和高排名的登记和积极的病人。
在新的P30 ADRC提案中,我们将在这些先前成就的基础上继续前进,
将被两个总目标所激励。第一个目标是,与前几个周期一样,
第二个目标是支持这一主题。我们建议实现这些目标
通过我们高度集成的核心,这些核心共同建立了一个基础架构,
资源生物标本和专业知识除了行政核心外,这些核心还包括临床核心
由Lawrence Honig博士领导,由霍华德安德鲁斯博士领导的“数据管理和统计”核心,
由Andrew Teich博士领导的神经病理学核心,由Adam Brickman博士领导的生物标志物核心,遗传学核心
由Christiane雷茨博士领导,菲利普德贾格尔博士领导的神经免疫学核心,一个“外展,保留,
由William(Ted)Huey博士领导的“参与”核心,以及由James Noble博士领导的“研究教育”模块。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SCOTT A SMALL其他文献
SCOTT A SMALL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SCOTT A SMALL', 18)}}的其他基金
Alzheimer's Disease Research Center Determinants of health seeking behaviors during COVID-19 in persons with MCI/ADRD and their caregivers
阿尔茨海默病研究中心 COVID-19 期间 MCI/ADRD 患者及其护理人员寻求健康行为的决定因素
- 批准号:
10218428 - 财政年份:2020
- 资助金额:
$ 311.35万 - 项目类别:
Longitudinal imaging of microglial activation in different clinical variants of Alzheimer's disease
阿尔茨海默病不同临床变体中小胶质细胞激活的纵向成像
- 批准号:
10404997 - 财政年份:2020
- 资助金额:
$ 311.35万 - 项目类别:
Longitudinal imaging of microglial activation in different clinical variants of Alzheimer's disease
阿尔茨海默病不同临床变体中小胶质细胞激活的纵向成像
- 批准号:
10633128 - 财政年份:2020
- 资助金额:
$ 311.35万 - 项目类别:
相似海外基金
Toward a Political Theory of Bioethics: Participation, Representation, and Deliberation on Federal Bioethics Advisory Committees
迈向生命伦理学的政治理论:联邦生命伦理学咨询委员会的参与、代表和审议
- 批准号:
0451289 - 财政年份:2005
- 资助金额:
$ 311.35万 - 项目类别:
Standard Grant